PDF(Pubmed)
Abstract：
BACKGROUND: Serum bone turnover markers might play a role in the prediction of the development of bone metastases in breast cancer (BC) patients. We conducted a retrospective cohort study to address the association of serum bone turnover markers with oncologic outcomes.
METHODS: We included 80 women with BC, who were operated on at the Department of Gynecology, Obstetrics and Reproductive Medicine, Homburg/Saar, Germany. Serum samples were obtained prior to surgery and were used for estimation of the concentration of tumor and bone turnover markers using enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA).
RESULTS: At baseline, pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen (ICTP) concentrations were higher in nodal positive vs. negative tumors (Mann-Whitney test p = 0.04). After a median follow-up of 79.4 months, 17 patients developed metastases, with 9 demonstrating, among other organs, osseous metastases. ICTP demonstrated the best area under the curve in the predection of osseous metastases in our cohort (AUC = 0.740, DeLong Test p = 0.005). Univariable Cox proportional hazard models failed to demonstrate significant associations between serum bone turnover markers and oncologic outcomes (progression-free survival, overall survival).
CONCLUSIONS: Serum bone turnover markers (e.g., ICTP) were able to predict the development of osseous metastases but were not associated with oncologic outcomes. Further investigation and validation are required for the use of such markers in clinical practice.
METHODS: We included 80 women with BC, who were operated on at the Department of Gynecology, Obstetrics and Reproductive Medicine, Homburg/Saar, Germany. Serum samples were obtained prior to surgery and were used for estimation of the concentration of tumor and bone turnover markers using enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA).
RESULTS: At baseline, pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen (ICTP) concentrations were higher in nodal positive vs. negative tumors (Mann-Whitney test p = 0.04). After a median follow-up of 79.4 months, 17 patients developed metastases, with 9 demonstrating, among other organs, osseous metastases. ICTP demonstrated the best area under the curve in the predection of osseous metastases in our cohort (AUC = 0.740, DeLong Test p = 0.005). Univariable Cox proportional hazard models failed to demonstrate significant associations between serum bone turnover markers and oncologic outcomes (progression-free survival, overall survival).
CONCLUSIONS: Serum bone turnover markers (e.g., ICTP) were able to predict the development of osseous metastases but were not associated with oncologic outcomes. Further investigation and validation are required for the use of such markers in clinical practice.
摘要：
背景：血清骨转换标志物可能在预测乳腺癌（BC）患者骨转移的发展中起作用。我们进行了一项回顾性队列研究，以解决血清骨转换标志物与肿瘤学结局的关联。
方法：我们纳入了80名女性，在妇科手术，产科和生殖医学，洪堡/萨尔,德国。手术前获得血清样品，并使用酶联免疫吸附测定（ELISA）和放射免疫测定（RIA）评估肿瘤和骨转换标志物的浓度。
结果：在基线时，1型胶原的吡啶啉交联羧基末端端肽（ICTP）浓度在淋巴结阳性与阴性肿瘤(Mann-Whitney检验p=0.04)。经过79.4个月的中位随访，17例患者发生转移，9个演示在其他器官中，骨转移。在我们的队列中，ICTP在骨转移前的曲线下显示出最佳面积（AUC=0.740，DeLong检验p=0.005）。单变量Cox比例风险模型未能证明血清骨转换标志物与肿瘤学结果(无进展生存期,总体生存率)。
结论：血清骨转换标志物(例如，ICTP）能够预测骨转移的发展，但与肿瘤学结果无关。在临床实践中使用此类标记物需要进一步的研究和验证。
方法：我们纳入了80名女性，在妇科手术，产科和生殖医学，洪堡/萨尔,德国。手术前获得血清样品，并使用酶联免疫吸附测定（ELISA）和放射免疫测定（RIA）评估肿瘤和骨转换标志物的浓度。
结果：在基线时，1型胶原的吡啶啉交联羧基末端端肽（ICTP）浓度在淋巴结阳性与阴性肿瘤(Mann-Whitney检验p=0.04)。经过79.4个月的中位随访，17例患者发生转移，9个演示在其他器官中，骨转移。在我们的队列中，ICTP在骨转移前的曲线下显示出最佳面积（AUC=0.740，DeLong检验p=0.005）。单变量Cox比例风险模型未能证明血清骨转换标志物与肿瘤学结果(无进展生存期,总体生存率)。
结论：血清骨转换标志物(例如，ICTP）能够预测骨转移的发展，但与肿瘤学结果无关。在临床实践中使用此类标记物需要进一步的研究和验证。
